Stone, Shane http://orcid.org/0000-0002-3356-2013
Henao, Maria P. http://orcid.org/0000-0002-7984-3072
Craig, Timothy J. http://orcid.org/0000-0002-7774-4855
Al-Shaikhly, Taha http://orcid.org/0000-0002-1251-8937
Funding for this research was provided by:
National Center for Advancing Translational Sciences (UL1 TR002014)
Article History
Received: 13 March 2024
Accepted: 24 April 2024
First Online: 24 May 2024
Declarations
:
: Shane Stone has nothing to disclose. Paula M Henao has nothing to disclose. Taha Al-Shaikhly has nothing to disclose. Timothy J. Craig is an editorial board member of the Pulmonary Therapy journal. Timothy J. Craig was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Timothy J. Craig has received research support from Astria, BioMarin, CSL Behring, GSK, Grfols, Intellia, Ionis, KalVista, Pfizer, Pharvaris, Regeneron, and Takeda; speaking fees from CSL Behring, Grifols, and Takeda; consult- ant fees from Astra, Biocryst, BioMarin, CSL Behring, Intellia, Ionis, Kalvista, and Takeda. He also has center designations from International Hereditary Angioedema Association and Alpha-1 Foundation and is a member of the Medical Advisory Board for the HAE-A.
: Ethical approval was not required for this study. This retrospective study is exempt from informed consent. The data reviewed is a secondary analysis of existing data, does not involve intervention or interaction with human subjects, and is de-identified per the de-identification standard defined in §164.514(a) of the HIPAA Privacy Rule. The process by which the data is de-identified is attested to through a formal determination by a qualified expert as defined in §164.514(b)(1) of the HIPAA Privacy Rule. This formal determination by a qualified expert refreshed on December 2020.